USPH

SEC source: 0001209191-21-023151 · doc4.xml · nonDerivative · entry 5

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,000

F1 · balance_after: Includes 400 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-21-023151 · doc4.xml · nonDerivative · entry 4

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 37,000

F1 · balance_after: Includes 400 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-21-023151 · doc4.xml · nonDerivative · entry 3

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,000

F1 · balance_after: Includes 400 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-21-023151 · doc4.xml · nonDerivative · entry 2

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,000

F1 · balance_after: Includes 400 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-21-023151 · doc4.xml · nonDerivative · entry 1

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

F1 · balance_after: Includes 400 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-21-020659 · doc4.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,600

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $121.61 to $122.37 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 400 shares of restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse as to 400 shares on April 1, 2021, if he is a director of the Company on those dates.

SEC source: 0001209191-21-018483 · doc4.xml · nonDerivative · entry 2

MCAFEE LAWRANCE W · CIK 0001263096 · Former Director, Exec VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,582

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.00 to $111.19 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-21-018483 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Former Director, Exec VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,082

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $110.21 to $111.51 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-21-017604 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,600

F1 · balance_after: Includes 400 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-21-015607 · doc4.xml · nonDerivative · entry 2

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · Reeve Trust

Disclosed balance after: 6,496

SEC source: 0001209191-21-015262 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Former Director, Exec VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,582

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $118.00 to $120.00 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-21-013683 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 81,638

F1 · shares: The 11,200 shares of common stock was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan of which 8,800 under the Companys Discretionary Long-Term Incentive Plan for Senior Management and 2,400 as an additional grant. Restrictions lapse in 16 equal quarterly installment with the first 700 shares on April 1, 2021 and thereafter with 700 shares on April 1, July 1, October 1 and January 1 of each year with the final 700 shares lapsing on January 1, 2025, if he is employed by the Company on those dates.

F2 · balance_after: Inclusive of the above 11,200 shares in footnote 1, includes 37,275 shares which restrictions lapse as to 4,141 shares on each of April 1, July 1 and October 1, 2021 and January 1, 2022; 2,876 on each of April 1, July 1 and October 1, 2022; 2,879 shares on January 1, 2023; 1,598 shares on each of April 1, July 1 and October 1, 2023; 1,610 shares on January 1, 2024; and 700 shares on each of April 1, July 1 and October 1, 2023 and January 1, 2025, if he is employed by the Company on those dates.

SEC source: 0001209191-21-013678 · doc4.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,944

F1 · shares: The 5,600 shares of common stock was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan of which 4,400 under the Companys Discretionary Long-Term Incentive Plan for Senior Management and 1,200 as an additional grant. Restrictions lapse in 16 equal quarterly installment with the first 350 shares on April 1, 2021 and thereafter with 350 shares on April 1, July 1, October 1 and January 1 of each year with the final 350 shares lapsing on January 1, 2025, if he is employed by the Company on those dates.

F2 · balance_after: Inclusive of the above 5,600 shares in footnote 1, includes 17, 944 shares which restrictions lapse as to 1,909 shares on each of April 1, July 1 and October 1, 2021; 1,912 shares on January 1, 2022; 1,433 on each of April 1, July 1 and October 1, 2022; 1,448 shares on January 1, 2023; 788 shares on each of April 1, July 1 and October 1, 2023; 794 shares on January 1, 2024; and 350 shares on each of April 1, July 1 and October 1, 2023 and January 1, 2025, if he is employed by the Company on those dates.

SEC source: 0001209191-21-013672 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,069

F1 · shares: The 5,600 shares of common stock was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan of which 4,400 under the Companys Discretionary Long-Term Incentive Plan for Senior Management and 1,200 as an additional grant. Restrictions lapse in 16 equal quarterly installment with the first 350 shares on April 1, 2021 and thereafter with 350 shares on April 1, July 1, October 1 and January 1 of each year with the final 350 shares lapsing on January 1, 2025, if he is employed by the Company on those dates.

F2 · balance_after: Inclusive of the above 5,600 shares in footnote 1, includes 17, 885 shares which restrictions lapse as to 2,009 shares on each of April 1, July 1 and October 1, 2021; 2,017 shares on January 1, 2022; 1,377 on each of April 1, July 1 and October 1, 2022; 1,380 shares on January 1, 2023; 729 shares on each of April 1, July 1 and October 1, 2023; 743 shares on January 1, 2024; and 350 shares on each of April 1, July 1 and October 1, 2023 and 350 shares on January 1, 2025, if he is employed by the Company on those dates.

SEC source: 0001209191-20-061820 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,438

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.64 - $107.60, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 30,551 shares which restrictions lapse as to 4,476 shares on January 1, 2021; 3,441 shares on each of April 1, July 1 and October 1, 2021 and January 1, 2022; 2,176 shares on each of April 1, July 1 and October 1, 2022; 2,179 shares on January 1, 2023; 898 shares on each of April 1, July 1 and October 1 2023 and 910 shares on January 1, 2024, if he is employed on those dates.

SEC source: 0001209191-20-061363 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,200

F1 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of January 1, 2021 and April 1, 2021, if he is a director of the Company on those dates.

SEC source: 0001209191-20-060675 · doc4.xml · nonDerivative · entry 1

Harris Bernard A Jr · CIK 0001337906 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,622

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 and $107.05, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of January 1, 2021 and April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-20-058608 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,600

F1 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of January 1, 2021 and April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-20-058461 · doc4.xml · nonDerivative · entry 1

Harris Bernard A Jr · CIK 0001337906 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,622

F1 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of January 1, 2021 and April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-20-057858 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,037

F1 · shares: Bona fide gift to a charitable organization.

F2 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on 400 shares on each of January 1, 2021 and April 1, 2021, if he is a director of the Company on that date.

SEC source: 0001209191-20-058216 · doc4.xml · nonDerivative · entry 2

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · Reeve Trust

Disclosed balance after: 6,137

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $103.86 to $104.59, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3 · balance_after: Shares are held in the Reeve Living Trust which Mr. Reeve is a trustee and beneficiary.

SEC source: 0001209191-20-058215 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,469

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $105.80 to $106.63, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 14,469 shares which restrictions lapse as to 2,184 shares on January 1, 2021; 1,659 shares on each of April 1, July 1 and October 1, 2021; 1,667 shares on January 1, 2022; 1,027 shares on each of April 1, July 1 and October 1, 2022; 1,030 shares on January 1, 2023; 379 shares on each of April 1, July 1 and October 1 2023 and 393 shares on January 1, 2024, if he is employed by the Company on those dates.

SEC source: 0001209191-20-057587 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Former Exec VP, CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,852

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $111.76 to $112.56, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 15,052 shares which restrictions lapse as to 2,229 shares on January 1, 2021; 1704 shares on each of April 1, July 1 and October 1, 2021; 1,712 shares on January 1, 2022; 1,072 shares on each of April 1, July 1 and October 1, 2022; 1,075 shares on January 1, 2023; 424 shares on each of April 1, July 1 and October 1 2023 and 436 shares on January 1, 2024, if he is employed by the Company on those dates.

SEC source: 0001209191-20-047421 · doc4.xml · nonDerivative · entry 1

Trier Clayton · CIK 0001319561 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,950

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse for 400 shares upon grant and 400 shares on each of October 1, 2020 and January 1 and April 1, 2021, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares noted in above footnote.

SEC source: 0001209191-20-047420 · doc4.xml · nonDerivative · entry 1

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,200

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse for 400 shares upon grant and 400 shares on each of October 1, 2020 and January 1 and April 1, 2021, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares noted in above footnote.

SEC source: 0001209191-20-047419 · doc4.xml · nonDerivative · entry 1

KUNTZ EDWARD L · CIK 0001182168 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,200

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse for 400 shares upon grant and 400 shares on each of October 1, 2020 and January 1 and April 1, 2021, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares noted in above footnote.

SEC source: 0001209191-20-047418 · doc4.xml · nonDerivative · entry 1

Harris Bernard A Jr · CIK 0001337906 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 27,622

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse for 400 shares upon grant and 400 shares on each of October 1, 2020 and January 1 and April 1, 2021, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares noted in above footnote.

SEC source: 0001209191-20-047417 · doc4.xml · nonDerivative · entry 1

Gilmartin Kathleen A · CIK 0001741732 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,200

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse for 400 shares upon grant and 400 shares on each of October 1, 2020 and January 1 and April 1, 2021, if she is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares noted in above footnote.

SEC source: 0001209191-20-047416 · doc4.xml · nonDerivative · entry 1

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,000

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse for 400 shares upon grant and 400 shares on each of October 1, 2020 and January 1 and April 1, 2021, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares noted in above footnote.

SEC source: 0001209191-20-047412 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,037

F1 · shares: The 1,600 shares of common stock were granted as restricted stock pursuant to the Company Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse for 400 shares upon grant and 400 shares on each of October 1, 2020 and January 1 and April 1, 2021, if he is a director of the Company on those dates.

F2 · balance_after: Includes the 1,600 shares noted in above footnote.

SEC source: 0001209191-20-046749 · doc4.xml · nonDerivative · entry 2

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · Reeve Trust

Disclosed balance after: 5,578

F2 · balance_after: Shares are held in the Reeve Living Trust which Mr. Reeve is a trustee and beneficiary.

SEC source: 0001209191-20-046245 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,074

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $90.84 to $92.83 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 17,266 shares which restrictions lapse as to 2,214 shares on October 1, 2020; 2,229 shares on January 1, 2021; 1704 shares on each of April 1, July 1 and October 1, 2021; 1,712 shares on January 1, 2022; 1,072 shares on each of April 1, July 1 and October 1, 2022; 1,075 shares on January 1, 2023; 424 shares on each of April 1, July 1 and October 1 2023 and 436 shares on January 1, 2024, if he is employed by the Company on those dates.

SEC source: 0001209191-20-034714 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,437

SEC source: 0001209191-20-034597 · doc4.xml · nonDerivative · entry 4

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,637

SEC source: 0001209191-20-034597 · doc4.xml · nonDerivative · entry 3

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,008

SEC source: 0001209191-20-034597 · doc4.xml · nonDerivative · entry 2

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,037

SEC source: 0001209191-20-034597 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,537

SEC source: 0001209191-20-032940 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,037

SEC source: 0001209191-20-033289 · doc4.xml · nonDerivative · entry 2

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Indirect · Reeve Trust

Disclosed balance after: 5,519

F2 · balance_after: Shares are held in the Reeve Living Trust, which Mr. Reeve is a trustee and beneficiary.

SEC source: 0001209191-20-020184 · doc4.xml · nonDerivative · entry 1

Chapman Harry S · CIK 0001500817 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,400

F1 · balance_after: Includes 400 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on April 1, 2020, if he is a director of the Company on that date.

SEC source: 0001209191-20-019916 · doc4.xml · nonDerivative · entry 2

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 6,596

F2 · balance_after: Regg E Swanson Revocable Trust is the owner, and Regg E Swanson is Beneficiary and Trustee

SEC source: 0001209191-20-019147 · doc4.xml · nonDerivative · entry 3

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 5,596

F2 · balance_after: Regg E Swanson Revocable Trust is the owner, and Regg E Swanson is Beneficiary and Trustee

SEC source: 0001209191-20-019147 · doc4.xml · nonDerivative · entry 2

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 4,812

F2 · balance_after: Regg E Swanson Revocable Trust is the owner, and Regg E Swanson is Beneficiary and Trustee

SEC source: 0001209191-20-016645 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 23,524

F1 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $107.00 to $108.55 per share, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc. any of its shareholders or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F2 · balance_after: Includes 21,694 shares which restrictions lapse as to 2,214 shares on each of April 1, July 1 and October 1, 2020; 2,229 shares on January 1, 2021; 1704 shares on each of April 1, July 1 and October 1, 2021; 1,712 shares on January 1, 2022; 1,072 shares on each of April 1, July 1 and October 1, 2022; 1,075 shares on January 1, 2023; 424 shares on each of April 1, July 1 and October 1 2023 and 436 shares on January 1, 2024, if he is employed by the Company on those dates.

SEC source: 0001209191-20-016493 · doc4.xml · nonDerivative · entry 1

REEVE GRAHAM D. · CIK 0001519948 · COO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,580

F1 · shares: The 7,014 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 438 shares on April 1, 2020 and thereafter with 438 shares on April 1, July 1, October 1 and January 1 of each year with the final 444 shares lapsing on January 1, 2024, if he is employed by the Company on those dates.

F2 · balance_after: Includes 18,580 shares which restrictions lapse as to 1,559 shares on each of April 1, July 1 and October 1, 2020 and 2021; 1,562 shares on January 1, 2022; 1,083 shares on each of April 1, July 1 and October 1, 2022; 1,098 shares on January 1, 2023; 438 shares on each of April 1, July 1 and October 1 2023 and 444 shares on January 1, 2024, if he is employed by the Company on those dates.

SEC source: 0001209191-20-016492 · doc4.xml · nonDerivative · entry 1

READING CHRISTOPHER J · CIK 0001270356 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 76,438

F1 · shares: The 14,380 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 898 shares on April 1, 2020 and thereafter with 898 shares on April 1, July 1, October 1 and January 1 of each year with the final 910 shares lapsing on January 1, 2024.

F2 · balance_after: Includes 43,937 shares which restrictions lapse as to 4,462 shares on each of April 1, July 1 and October 1, 2020; 4,476 shares on January 1, 2021; 3,441 shares on each of April 1, July 1 and October 1, 2021 and on January 1, 2022; 2,176 shares on each of April 1, July 1 and October 1, 2022; 2,179 shares on January 1, 2023; 898 shares on each of April 1, July 1 and October 1 2023 and 910 shares on January 1, 2024.

SEC source: 0001209191-20-016491 · doc4.xml · nonDerivative · entry 1

McDowell Glenn · CIK 0001315304 · Chief Operating Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 25,976

F1 · shares: The 6,078 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 379 shares on April 1, 2020 and thereafter with 379 shares on April 1, July 1, October 1 and January 1 of each year with the final 393 shares lapsing on January 1, 2024, if he is employed by the Company on those dates.

F2 · balance_after: Includes 20,976 shares which restrictions lapse as to 2,169 shares on each of April 1, July 1 and October 1, 2020; 2,184 shares on January 1, 2021; 1,659 shares on each of April 1, July 1 and October 1, 2021; 1,667 shares on January 1, 2022; 1,027 shares on each of April 1, July 1 and October 1, 2022; 1,030 shares on January 1, 2023; 379 shares on each of April 1, July 1 and October 1 2023 and 393 shares on January 1, 2024, if he is employed by the Company on those dates.

SEC source: 0001209191-20-016490 · doc4.xml · nonDerivative · entry 1

MCAFEE LAWRANCE W · CIK 0001263096 · Director · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,524

F1 · shares: The 6,796 shares of common stock was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions lapse in 16 equal quarterly installment with the 424 shares on April 1, 2020 and thereafter with 424 shares on April 1, July 1, October 1 and January 1 of each year with the final 436 shares lapsing on January 1, 2024, if he is employed by the Company on those dates.

F2 · balance_after: Includes 21,694 shares which restrictions lapse as to 2,214 shares on each of April 1, July 1 and October 1, 2020; 2,229 shares on January 1, 2021; 1704 shares on each of April 1, July 1 and October 1, 2021; 1,712 shares on January 1, 2022; 1,072 shares on each of April 1, July 1 and October 1, 2022; 1,075 shares on January 1, 2023; 424 shares on each of April 1, July 1 and October 1 2023 and 436 shares on January 1, 2024, if he is employed by the Company on those dates.

SEC source: 0001209191-20-014179 · doc4.xml · nonDerivative · entry 2

Swanson Regg E. · CIK 0001412473 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 4,596

F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.00 - $102.75, both inclusive. The reporting person undertakes to provide to U.S. Physical Therapy, Inc., any of its shareholders or the staff of the Securities & Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

F3 · balance_after: Regg E Swanson Revocable Trust is the owner, and Regg E Swanson is Beneficiary and Trustee.

SEC source: 0001209191-19-059828 · doc4.xml · nonDerivative · entry 1

BROOKNER MARK J · CIK 0000938954 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,850

F1 · balance_after: Includes 800 shares of common stock which was granted as restricted stock pursuant to the Company's Amended and Restated 2003 Stock Incentive Plan. Restrictions will lapse on the 400 shares on each of January 1, 2020 and April 1, 2020, if he is a director of the Company on those dates.